Agrawal Deepak, Chen Tingan, Irby Rosalyn, Quackenbush John, Chambers Ann F, Szabo Marianna, Cantor Alan, Coppola Domenico, Yeatman Timothy J
Department of Cell Biology, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.
C R Biol. 2003 Oct-Nov;326(10-11):1041-3. doi: 10.1016/j.crvi.2003.09.007.
Identifying molecular markers for colon cancer is a top priority. Using a pooled sample approach with Affymetrix GeneChip technology, we assayed colon cancers derived from a series of clinical stages to identify molecular markers of potential prognostic value. Of 12000 genes assessed, osteopontin emerged as the leading candidate tumor progression marker. Osteopontin is a secreted glycoprotein known to bind integrins and CD44. Its actual molecular function remains elusive but its increased expression correlates strongly with tumor progression.
确定结肠癌的分子标志物是当务之急。我们采用Affymetrix基因芯片技术的混合样本方法，对一系列临床阶段的结肠癌进行检测，以确定具有潜在预后价值的分子标志物。在评估的12000个基因中，骨桥蛋白成为主要的候选肿瘤进展标志物。骨桥蛋白是一种已知能结合整合素和CD44的分泌型糖蛋白。其实际分子功能仍不清楚，但其表达增加与肿瘤进展密切相关。
